EA200100899A1 - ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ) - Google Patents

ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)

Info

Publication number
EA200100899A1
EA200100899A1 EA200100899A EA200100899A EA200100899A1 EA 200100899 A1 EA200100899 A1 EA 200100899A1 EA 200100899 A EA200100899 A EA 200100899A EA 200100899 A EA200100899 A EA 200100899A EA 200100899 A1 EA200100899 A1 EA 200100899A1
Authority
EA
Eurasian Patent Office
Prior art keywords
variants
identification
molecules
inhibitors
cpla2
Prior art date
Application number
EA200100899A
Other languages
English (en)
Inventor
Андре Десен
Джасбир С. Сеера
Уильям С. Сомерс
Марк Л. Стал
Original Assignee
Джинетикс Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинетикс Инститьют, Инк. filed Critical Джинетикс Инститьют, Инк.
Publication of EA200100899A1 publication Critical patent/EA200100899A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

В данном изобретении представлена кристаллическая cPLA. С использованием данного материала была также установлена кристаллическая структура cPLA. Кроме того, предложены модели на основе данной кристаллической структуры. Описаны также способы идентификации ингибиторов активности и связывания мембраны cPLAс помощью данных моделей.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100899A 1999-02-15 2000-02-14 ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ) EA200100899A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/250,083 US6801860B1 (en) 1999-02-15 1999-02-15 Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
PCT/US2000/003745 WO2000047763A1 (en) 1999-02-15 2000-02-14 CRYSTAL STRUCTURE OF cPLA2, AND METHODS OF IDENTIFYING AGONISTS AND ANTAGONISTS USING SAME

Publications (1)

Publication Number Publication Date
EA200100899A1 true EA200100899A1 (ru) 2002-04-25

Family

ID=22946256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100899A EA200100899A1 (ru) 1999-02-15 2000-02-14 ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)

Country Status (23)

Country Link
US (1) US6801860B1 (ru)
EP (1) EP1155144A4 (ru)
JP (1) JP2002540766A (ru)
KR (1) KR20010103010A (ru)
CN (1) CN1238520C (ru)
AU (1) AU779488B2 (ru)
BG (1) BG105886A (ru)
BR (1) BR0008231A (ru)
CA (1) CA2362612A1 (ru)
CZ (1) CZ20012933A3 (ru)
EA (1) EA200100899A1 (ru)
EE (1) EE200100426A (ru)
HK (1) HK1040745A1 (ru)
HR (1) HRP20010678A2 (ru)
HU (1) HUP0200554A3 (ru)
IL (1) IL144673A0 (ru)
MX (1) MXPA01008192A (ru)
NO (1) NO20013947L (ru)
NZ (1) NZ514176A (ru)
PL (1) PL351242A1 (ru)
SK (1) SK11782001A3 (ru)
TR (1) TR200102366T2 (ru)
WO (1) WO2000047763A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7792645B2 (en) 2000-08-30 2010-09-07 The Salk Institute For Biological Studies Three-dimensional structure of chalcone isomerase and methods of use thereof
EP1329511A4 (en) * 2000-09-19 2005-01-19 Kyowa Hakko Kogyo Kk POLYPEPTIDE WITH PHOSPHOLIPASE A2 ACTIVITY
AU2001218841A1 (en) * 2000-11-07 2002-05-21 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
CA2439182C (en) * 2001-02-22 2009-04-14 Japan Science And Technology Corporation Novel calcium-independent phospholipases a2, genes thereof and promoter of the same
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
KR20060105429A (ko) * 2003-05-22 2006-10-11 메타프로테오믹스, 엘엘씨 염증을 약화시키기 위한 항염증성 약제학적 조성물 및 위의독성의 치료법 또는 예방법
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
CN101444139A (zh) * 2004-11-13 2009-05-27 麦特普罗泰欧米克斯有限公司 抑制环氧合酶-2的组合物
US7931904B2 (en) 2005-02-15 2011-04-26 Dana Farber Cancer Institute, Inc. Modulation of MUC1 activity
US8263139B2 (en) * 2005-08-09 2012-09-11 Metaproteonics, Llc Protein kinase modulation by hops and Acacia products
WO2007024940A2 (en) 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
US20070154576A1 (en) * 2005-12-09 2007-07-05 Tripp Matthew L Protein kinase modulation by hops and Acacia products
WO2007149503A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc. Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008101121A2 (en) 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008115783A1 (en) * 2007-03-19 2008-09-25 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
CA2686043A1 (en) 2007-05-11 2008-11-20 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
US20100137449A1 (en) * 2007-12-10 2010-06-03 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
US20100222262A1 (en) * 2008-04-02 2010-09-02 Metaproteomics, Llc Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
AU2009305550B2 (en) 2008-10-17 2014-06-12 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
MX2015011873A (es) 2013-03-15 2016-01-25 Bayer Healthcare Llc Dominios gla como agentes de direccionamiento.
MX2020002250A (es) 2017-09-05 2020-09-18 Gladiator Biosciences Inc Suministro de cargas utiles a las celulas madre.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622832A (en) 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
CA2061738A1 (en) * 1991-03-01 1992-09-02 Ruth M. Kramer Antibodies reactive with human cytosolic phospholipase a2
IL101507A0 (en) 1991-04-17 1992-12-30 Lilly Co Eli Compounds,vectors and methods for expressing human,cytosolic phospholipase a2
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5466595A (en) 1994-07-27 1995-11-14 Genetics Institute, Inc. Calcium independent cytosolic phospholipase A2/B enzymes

Also Published As

Publication number Publication date
BG105886A (en) 2002-05-31
HRP20010678A2 (en) 2003-08-31
PL351242A1 (en) 2003-04-07
CA2362612A1 (en) 2000-08-17
EE200100426A (et) 2002-12-16
EP1155144A4 (en) 2002-08-28
MXPA01008192A (es) 2002-10-23
HUP0200554A3 (en) 2006-06-28
NO20013947D0 (no) 2001-08-14
KR20010103010A (ko) 2001-11-17
NO20013947L (no) 2001-10-10
CN1238520C (zh) 2006-01-25
BR0008231A (pt) 2001-10-30
AU779488B2 (en) 2005-01-27
SK11782001A3 (sk) 2002-03-05
US6801860B1 (en) 2004-10-05
CZ20012933A3 (cs) 2002-02-13
WO2000047763A1 (en) 2000-08-17
JP2002540766A (ja) 2002-12-03
HK1040745A1 (zh) 2002-06-21
NZ514176A (en) 2004-09-24
HUP0200554A2 (en) 2002-06-29
IL144673A0 (en) 2002-05-23
CN1348502A (zh) 2002-05-08
AU2993700A (en) 2000-08-29
TR200102366T2 (tr) 2002-02-21
EP1155144A1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
EA200100899A1 (ru) ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)
ATE338951T1 (de) Vorrichtung zur automatischen durchführung von laboratoriumprüfungen
DE69735445D1 (de) Abspaltbare, nicht-flüchtige moleküle zur massenmarkierung
DE60116322D1 (de) Vorrichtung zur aktiven kompensation von aberrationen in einem optischen system
BRPI0515079A (pt) marcadores imobilizados e métodos de detecção de prions conformacionalmente alterados
BRPI0002963B1 (pt) processo e dispositivo medidor eletroquìmico para medir uma concentração de analito em uma amostra.
DE69917372D1 (de) Vorrichtung zur Quantifizierung von Substraten
DE60026688D1 (de) Vorrichtung zur fokussierter probennahme von formations flüssigkeit.
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
BR0009206A (pt) Isolamento e análise de proteina
FR2847267B1 (fr) Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2
WO2001042786A3 (en) System for cell based screening : cell spreading
ATE335845T1 (de) Elektrophoretische analyse von molekülen mit immobilisierten sonden
DE60041355D1 (de) Verfahren zur detektion von erkrankungen
DE69941688D1 (de) Immunoassays unter verwendung von sers (surface enhanced raman scattering)
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
BR9812783A (pt) "sistemas de detecção para o registro de interações e as relações funcionais de proteìnas"
ATE415485T1 (de) Sensoranordnung, vorrichtung und verfahren zur amperometrischen und/oder potentiometrischen, pharmakologischen wirkort- und/oder wirkstofftestung
EA200401628A1 (ru) Ингибиторы пептидной деформилазы
DE60311973D1 (de) Substrat und verfahren zum messen elektrophysiologischer eigenschaften von zellmembranen
DE60029413D1 (de) Enzymatische messung von mycophenolsäure
DE60132729D1 (de) Verfahren und Vorrichtung zur Erfassung von Azimutinformation
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
ATE288589T1 (de) Verfahren zur analyse von proteinen
ATE514082T1 (de) Biologischer bodendetektor